White shoe seeks blue blood
Euromoney, is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024
Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

White shoe seeks blue blood

Will Cazenove's blue-blood culture and exclusive corporate clientele be under threat in its joint venture with JPMorgan? Rivals would like to think so but the two parties are aware of how crucial these features are. What's more, there's nowhere much else for top corporate customers to go. The biggest danger is that the merged firm will cater for so many blue chips in such sectors as mining that conflicts of interest might emerge.

Winters, Mayhew and Pickering: Mayhew
will chair the joint venture which, he claims,
will add to Cazenove's "relevance".

THE JOINT VENTURE between JPMorgan and Cazenove will reshape the investment banking landscape in the UK, the second biggest investment banking market in the world, regardless of whether it succeeds or fails.

The impact of the deal will be felt as soon as it becomes effective in the first quarter of 2005. Based on deals so far this year, the new company, with a market share of nearly 40%, would topple Goldman Sachs from the top of the UK M&A league table. The firm would also rise to the number three spot in European M&A, knocking Deutsche Bank out of the top 10. JPMorgan Cazenove would also become the number three in UK equity capital markets, with a market share of 11.5%, nudging Citigroup out of the top five.

Cazenove has close long-term advisory relationships with 43 of the top 100 quoted companies in the UK and 235 others. Cazenove's clients turn to it for advice they can trust and the bank's stability, independence, culture and the narrow focus of its business model have been its hallmark and strength for 181 years.

Gift this article